For Healthcare Professionals
Choose TECVAYLI™, the first bispecific BCMA × CD3 T-cell engager given as an off-the-shelf subcutaneous injection for adult patients with RRMM who have received at least 4 prior lines of therapy, including a PI, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1,2
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
*ORR: sCR+CR+VGPR+PR.
†≥CR: sCR+CR.
MajesTEC-1 study design: The efficacy of TECVAYLI™ was evaluated in patients with RRMM in a single-arm, open-label, multi-center, phase 1/2 study. The study included patients who had previously received at least 3 prior therapies, including a PI, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1
Register to stay up-to-date with important information about TECVAYLI™
Talk to a Janssen Oncology representative and ask them your questions
about TECVAYLI™
Access resources to help patients receive TECVAYLI™
BCMA, B-cell maturation antigen; CD3, cluster of differentiation 3; CD38, cluster of differentiation 38; CI, confidence interval; CR, complete response; ORR, overall response rate; PI, proteasome inhibitor; PR, partial response; RRMM, relapsed or refractory multiple myeloma; sCR, stringent complete response; VGPR, very good partial response.
References:
- TECVAYLI™ (teclistamab-cqyv) Prescribing Information. Janssen Biotech, Inc., Horsham, PA 19044.
- US Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Accessed March 7, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma